









Markets
/
Stocks
/
nasdaq-imtx
/

Immatics NV

IMTX

9.630USD

+1.060+12.37%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.17BMarket Cap

LossP/E TTM



Immatics NV

9.630

+1.060+12.37%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immatics NV

Currency: USD Updated: 2026-02-06

Key Insights

Immatics NV's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 67 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immatics NV's Score

Industry at a Glance

Industry Ranking

67 / 392

Overall Ranking

187 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Immatics NV Highlights

StrengthsRisks

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -12.74, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 94.12M shares, decreasing 17.17% quarter-over-quarter.

Held by Wasatch Global Investors

Star Investor Wasatch Global Investors holds 718.90K shares of this stock.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

18.800

Target Price

+101.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Immatics NV is 6.38, ranking 260 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 4.48M, representing a year-over-year decrease of 90.62%, while its net profit experienced a year-over-year decrease of 439.36%.

Score

Industry at a Glance

Previous score

6.38

Change



Financials

9.33

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.17

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Immatics NV's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Immatics NV is 7.18, ranking 157 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -12.74, which is -519.01% below the recent high of 53.38 and -240.63% above the recent low of -43.40.

Score

Industry at a Glance

Previous score

7.18

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Immatics NV is 8.91, ranking 39 out of 392 in the Biotechnology & Medical Research industry. The average price target is 17.50, with a high of 25.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.91

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

18.800

Target Price

+101.28%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Immatics NV

IMTX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Immatics NV is 7.27, ranking 84 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.60 and the support level at 8.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.35

Change

0.92

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.094

Sell

RSI(14)

49.077

Neutral

STOCH(KDJ)(9,3,3)

34.943

Neutral

ATR(14)

0.621

High Vlolatility

CCI(14)

-91.824

Neutral

Williams %R

46.000

Neutral

TRIX(12,20)

-0.168

Sell

StochRSI(14)

80.935

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

9.496

Buy

MA10

9.583

Buy

MA20

9.652

Sell

MA50

9.980

Sell

MA100

9.656

Sell

MA200

7.645

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Immatics NV is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 77.43%, representing a quarter-over-quarter decrease of 2.81%. The largest institutional shareholder is PRFDX, holding a total of 724.81K shares, representing 0.60% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Investment Management, Inc.

19.38M

+5.75%

DH Capital GmbH & Co. KG

17.20M

Baker Bros. Advisors LP

12.09M

+18.93%

Suvretta Capital Management, LLC

12.03M

Perceptive Advisors LLC

9.38M

RTW Investments L.P.

8.82M

+26.48%

Vestal Point Capital, LP

6.35M

+1.60%

TD Securities, Inc.

5.12M

+75.87%

Sofinnova Investments, Inc

2.23M

-0.57%

Morgan Stanley & Co. LLC

2.13M

+3.28%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Immatics NV is 4.44, ranking 87 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.38. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.